Legal Representation
Attorney
Frances M. Jagla
USPTO Deadlines
Next Deadline
78 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
October 22, 2025
Extension Available
Until October 22, 2025
Application History
17 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 16, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 15, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Apr 15, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Apr 15, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 22, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 27, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 27, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 7, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 18, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 17, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jul 17, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 17, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 17, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jul 16, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 26, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 26, 2024 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Dec 18, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of oncological, hematological, inflammatory and autoimmune disorders, rare and orphan disorders, endocrine disorders
Class 042
Scientific and medical research relating to oncological, hematological, inflammatory and autoimmune disorders, rare and orphan disorders, endocrine disorders
Class 044
Providing online healthcare and medical information to patients and healthcare providers relating to oncological, hematological, inflammatory and autoimmune disorders, rare and orphan disorders, endocrine disorders
Additional Information
Design Mark
The mark consists of the word "Protagonist" above the word "Therapeutics" to the left of the words is a DNA double helix.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"